tbuckley/cabot-search huggingface dataset:
Abstract 2560: Stent Thrombosis Predictors in Everyday Practice: Insights from the 7000-Patient TAXUS ARRIVE Registry Program
Authors: John M Lasala, David A Cox, Stephen R Mascioli, Donald S Baim
Journal: Circulation (2007)

Background: Risk factors associated with stent thrombosis (ST) of drug-eluting stents (DES) include acute coronary syndrome, stented length, and thienopyridine non-compliance. Predictive analyses for ST&gt;30 days can be limited by low event numbers. The objective of this study was to identify baseline ST predictors at 1 and 2 years (yr) using a pooled analysis of &gt;7000 registry patients (pts) to help guide individual pt therapy. Methods: Analysis included consecutively-enrolled pts (N=7307; 99 US sites) who received the TAXUS ® Express 2 paclitaxel-eluting stent (Boston Scientific, Natick, MA) DES and were prescribed long-term aspirin and minimally 6 months (M) thienopyridine therapy per the product label. Events were adjudicated by an independent Clinical Events Committee using Academic Research Consortium (ARC) ST definitions. Over 30 baseline characteristics were assessed as potential predictors of ST using backward step-wise Cox proportional hazards regression. Results: Predictors for ST&lt;1 yr and very late ST (VLST) differed except for discontinuation of thienopyridine before 6M, which was a strong predictor in both time intervals. For ST&lt;1 yr predictors were based on lesion characteristics (calcification, long lesions, multiple stents in a vessel, and small vessels) as well as pt-related factors such as smoking at baseline and congestive heart failure. Predictors of VLST&gt;1 yr included more biologic factors such as prior myocardial infarction and age. At time of event, 31% of VLST pts were on dual antiplatelet therapy; in contrast, 59% of ARRIVE pts overall continued thienopyridine therapy at 2 yrs. Conclusions: Differences in predictors for ST before and after 1 year suggest differences in pathophysiology. Dual antiplatelet therapy may be useful during year 2 after DES. Determination of DES baseline predictors may help identify pts at highest risk for late ST and VLST. Predictor analyses for high-risk subgroups in ARRIVE will be available in November. Table 1. Predictors of Stent Thrombosis in the TAXUS ARRIVE Registry
IgM Production in Rats Infected With Moloney Leukemia Virus 2
Authors: Natalie E. Cremer, Dee O. N. Taylor, Edwin H. Lennette, Shirley J. Hagens
Journal: JNCI Journal of the National Cancer Institute (1973)

Average serum IgM concentration of unstimulated rats infected with Moloney leukemia virus (MLV) was equal to or greater than that of unstimulated normal rats. After antigenic stimulation with Salmonella typhi “O” antigen, serum IgM of infected and normal rats increased, with the normal rats reaching a slightly but not significantly greater serum concentration. The average half life of IgM was 60–64 hours in both infected and normal rats. MLV antigen was present in 15–41% of the IgM-producing cells in popliteal lymph nodes (PLN) of infected rats. The number of IgM-producing cells in the PLN of infected 6-week-old rats was approximately equal to that in normal PLN but was reduced by 28–40% in 3- to 4-month-old infected rats. Serum IgM concentrations did not reflect this reduction, which suggested that PLN cells were not the major producers of IgM. Average antibody titers of infected rats after intravenous hyperimmunization with 5. typhi “O” antigen did not differ significantly from normal. Since all of the infected rats were viremic, and many were overtly lymphomatous with thymus weights over 5 grams, it is concluded that MLV infection does not significantly depress IgM synthesis and that a normal functioning thymus is not essential for IgM production in these rats.
Synergistic Effect of Cardiovascular Risk Factors on Necrotic Core in Coronary Arteries
Authors: Héctor M. García-García, Patrick W. Serruys, Gary S. Mintz, Satoshi Saito, Volker Klaus, Pauliina Margolis, Stephane Carlier, Dick Goedhart, Robert Schwartz
Journal: JACC. Cardiovascular imaging (2009)
Abstract 10088: Outcomes of Children Implanted with Ventricular Assist Devices in the United States: Analysis of the Interagency Registry for Mechanical Circulatory Support (INTERMACS)
Authors: David L Morales, Adam W Lowry, Deirdre J Epstein, David N Rosenthal, Jonathan M Chen, Christopher S Almond, Peter D Wearden, David C Naftel, James K Kirklin, Elizabeth D Blume
Journal: Circulation (2011)

INTRODUCTION: Pediatric mechanical circulatory support (MCS) has gained increasing attention as a strategy to decrease mortality in those awaiting transplant. Pediatric specific ventricular assist ...
Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib
Authors: E. Razis, P. Selviaridis, J. Fletcher, S. Labropoulos, R. Caprioli, G. Karkavelas, M. Zhu, T. Kalebic, J. Norris, G. Fountzilas
Journal: Journal of Clinical Oncology (2007)

2023 Background: Glioblastoma multiforme (GBM) carries a grave prognosis. There are phase I-II studies indicating that imatinib is active in GBM in pre-treated patients. To better understand the molecular basis of imatinib’s activity in this disease we performed a pharmacodynamic neoadjuvant study with imatinib in GBM. Methods: Patients underwent CT guided biopsy of their brain tumors. If diagnosed with GBM they were immediately treated with 7 days of imatinib 400mg po BID followed by either definitive surgery or, if that was not feasible, followed by re-biopsy. Corticosteroid dose was stable during this period and valproic acid was the only anti-epileptic drug allowed in order to avoid pharmacokinetic interaction with imatinib. Treatment after recovery was as per usual institutional policy. Pre and post treatment tissue specimens were analyzed by immunohistochemistry, proteomic technology and molecular biological methods. Pharmacokinetic studies were also performed. Results: Twenty patients were enrolled in 2 institutions with a median age of 64, of which 14 were male and 6 female. PS was 0 in 2, 1 in 9 and 2 in 9. Seventeen patients had pure GBM, 2 had mixed GBM with astrocytoma and one had anaplastic astrocytoma. Eighteen patients had stable disease on pre and post treatment MRI, one had progressed and one was not evaluable. Median survival was 6.2 months (1.1–18mo). Intact imatinib was quantified in the post treatment tissue specimens and correlations were made with serum imatinib levels per patient. No correlation was seen. Tissue specimens were analyzed by in situ MALDI mass spectroscopy and differential protein expression profiles were detected, when pre and post treatment specimens were compared. The identification of candidate proteins is ongoing. In 11 patients with evaluable, high-quality, matched pre and post imatinib biopsies, 4 had biochemical evidence of tumor response (decreased AKT or MAPK, or increased p27). In addition, 2 patients showed high-level EGFR activation, and one patient had high-level PDGFR activation. Conclusions: Treatment of GBM patients with imatinib results in measurable levels of the drug in the tumor. Potential indicators of biochemical response in a subset of patients were identified. No significant financial relationships to disclose.
Drug Treatment of Chronic Venous Insufficiency and Venous Ulceration: A Review
Authors: T R Cheatle, J H Scurr, P D Coleridge Smith
Journal: Journal of the Royal Society of Medicine (1991)

Treatment of venous insufficiency and venous ulceration has for many years relied on established principles of compression and limb elevation. Drug treatment has been of little benefit. In recent years, a better understanding of the pathological mechanisms underlying skin damage in venous disease has allowed more rational pharmacotherapeutic approaches to be made. This review examines these, with special reference to current theories of the cause of venous ulceration.
Prevalence and incidence of major depression in Alzheimer's disease
Authors: M F Weiner, S D Edland, H Luszczynska
Journal: American Journal of Psychiatry (1994)

This study examined the prevalence and incidence of major depressive disorder in Alzheimer's disease.The authors retrospectively reviewed two large Alzheimer's disease databases, one at the University of Texas Southwestern Medical Center in Dallas and the other at the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). The Dallas series contained 264 cases of Alzheimer's disease, of which 153 patients were followed up for an average of 3 years from initial evaluation. The CERAD database contained 1,095 cases and excluded patients with histories of depression at initial evaluation; 325 of these patients were followed up for at least 2 years. Alzheimer's disease was diagnosed according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; major depression was diagnosed according to the DSM-III-R criteria. Most of the patients in these series were dwelling in the community and had had Alzheimer's disease symptoms for approximately 4 years at the time of evaluation.In the Dallas series there was a 1.5% prevalence and a 0% incidence of major depression. In the CERAD series there was a 1.3% 2-year incidence of major depression.The low prevalence and incidence of DSM-III-R major depression in these patients suggest that for the period of time the patients were followed up, Alzheimer's disease did not predispose to major depression. However, major depression may herald the subsequent onset of dementia. Depression in dementia should perhaps be diagnosed by different criteria.
Abstract 12952: Deep Sequencing Reveals Distinct Right Ventricular miRNA Signature in Failing Human Heart
Authors: Kai-Chien Yang, Thomas G Di Salvo
Journal: Circulation (2014)

Introduction:  Right ventricular (RV) dysfunction contributes critically to the pathophysiology of congestive heart failure (HF). Impaired RV function independently predicts the mortality in patients with advanced HF. It has been well-documented that miRNA dysregulation in left ventricle (LV) plays an important role in pathogenesis of HF; however, it remains unclear how miRNAs are regulated in RV during HF.   Methods and Results:  Deep sequencing of small RNAs was conducted using RNA isolated from paired RV and LV samples from non-failing (NF) hearts (n=5), as well as from the RV of dilated non-ischemic (DCM, n=11) and ischemic (ICM, n=11) human failing hearts. A total of 624697446 sequencing reads were obtained and 492 miRNAs were detected in the human cardiac samples. Twenty-four miRNAs are differentially expressed in non-failing LV and RV samples (absolute fold-change≧1.2, adjusted P   Conclusions:  Although less than 5% of the myocardial miRNAs express differentially in RV and LV at baseline, myocardial miRNome responds to HF with marked differences between ventricular chambers. The distinct miRNA expression signature may contribute to the unique RV remodeling process with HF. Targeting RV-specific miRNA dysregulation may provide a novel therapeutic approach against RV dysfunction during HF.
PULMONARY PARAGONIMIASIS: REPORT OF A CASE
Authors: D H HARTER, S I MORSE
Journal: Annals of Internal Medicine (1959)

Case Reports1 November 1959PULMONARY PARAGONIMIASIS: REPORT OF A CASEDONALD H. HARTER, M.D., STEPHEN I. MORSE, M.D.DONALD H. HARTER, M.D.Search for more papers by this author, STEPHEN I. MORSE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-51-5-1104 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPulmonary paragonimiasis has rarely been studied in the United States. The case to be presented, the first admitted to the Columbia-Presbyterian Medical Center, afforded an unusual opportunity for the investigation of this disease, which is found predominantly in the Orient.CASE REPORTA 29 year old Chinese merchant marine officer was admitted to the Medical Service of the Presbyterian Hospital in March, 1956, because of 16 months of cough productive of blood-tinged sputum.There was no history of parasitic disease or serious illness in any member of his immediate family. In the past the patient had had four episodes of...Bibliography1. Ball JD: Tropical pulmonary eosinophilia, Tr. Roy. Soc. Trop. Med. and Hyg. 44: 237-258, 1950. CrossrefMedlineGoogle Scholar2. TillmanPhillips AJJS: Pulmonary paragonimiasis, Am. J. Med. 5: 167-187, 1948. CrossrefMedlineGoogle Scholar3. RoqueLudwickBell FTRWJC: Pulmonary paragonimiasis: a review with case reports from Korea and the Philippines, Ann. Int. Med. 38: 1206-1221, 1953. LinkGoogle Scholar4. Lee WH: Roentgen diagnosis of pulmonary paragonimiasis, Mem. College Med. Nat. Taiwan Univ. 4: 23-28, 1955. Google Scholar5. ChungHou HLTC: Chemotherapy of paragonimiasis: further observations on the efficacy of chloroquine, Chinese M. J. 72: 407-427, 1954. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication June 2, 1958.From the Department of Medicine, Columbia University College of Physicians and Surgeons, and the Presbyterian Hospital, New York, N. Y.Requests for reprints should be addressed to Donald H. Harter, M.D., Columbia-Presbyterian Medical Center, 622 West 168th Street, New York 32, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWurminfektionen des Menschen 1 November 1959Volume 51, Issue 5Page: 1104-1109KeywordsAttentionEosinophiliaHospital medicineParasitic diseasesProteinsRespirationSputumSurgeonsTropical diseasesTuberculosis ePublished: 1 December 2008 Issue Published: 1 November 1959 PDF downloadLoading ...
Mechanism of long-lasting suppression against Th2 immune response in the lung by a novel antedrug TLR7 agonist
Authors: Kazuo Eiho, Hiroyuki Matsui, Hideyuki Hayashi, Ryosaku Inagaki, Mikio Aoki, Mark Biffen, Andrew Leishman, Susan Edwards, Clare Murray, Haruo Takaku, Hideyuki Tomizawa, Shizuo Akira, Yutaka Ueda
Journal: European Respiratory Journal (2011)

Rationale:  To identify the mechanisms by which a novel antedrug Toll like receptor 7 (TLR7) agonist, AZ12441970, mediates the long-lasting suppression of Th2 immune responses.   Methods:  Long-lasting efficacy of AZ12441970 against bronchoalveolar lavage (BAL) eosinophilia was investigated utilizing Ovalbumin (OVA)/Alum-sensitised mice or OVA-specific Th2 cells adoptively transferred into mice. The mechanism by which AZ12441970 mediated long-lasting efficacy was investigated utilizing T cell-deficient nude mice and several knock-out (KO) mice including type I IFN receptor KO mice, B cell KO mice and rag2 KO mice lacking B and T cells.   Results:  Weekly lung doses of AZ12441970 for 6 weeks significantly inhibited BAL eosinophilia for at least 6 weeks following cessation of dosing. The long-lasting efficacy observed with the compound was largely abolished in type I IFN receptor KO mice, rag2 KO mice or nude mice, but maintained in B cell KO mice. T cells were shown to be involved in the mechanism of efficacy in a T cell reconstituted nude mouse model of allergic airways inflammation. Nose only exposure of AZ12441970 also resulted in long-term efficacy in the lung.   Conclusions:  We show that intranasal dosing of AZ12441970 to achieve lung exposure in mice induces a long-lasting efficacy against Th2 immune responses in the lung. The efficacy in the lung is also achieved by nose only exposure of the TLR7 agonist. Furthermore, our mechanism studies demonstrate that the long-lasting inhibition of the Th2 immune responses with the compound is IFN-α- and T-cell-dependent. These data suggest that novel antedrug TLR7 agonists may have potential in the treatment of allergic disease.
Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer
Authors: Robert J. Motzer, Joel Sheinfeld, Madhu Mazumdar, Manjit Bains, Tania Mariani, Jennifer Bacik, Dean Bajorin, George J. Bosl
Journal: Journal of Clinical Oncology (2000)

PURPOSE: To evaluate the dose, toxicity, and efficacy of paclitaxel in combination with ifosfamide and cisplatin as salvage therapy for patients with relapsed testicular germ cell tumors (GCTs). PATIENTS AND METHODS: Thirty patients with previously treated GCTs were treated with paclitaxel and ifosfamide plus cisplatin (TIP) as second-line therapy. All had favorable prognostic features for response (testis primary tumor site and prior complete response to first-line chemotherapy program). Four cycles of paclitaxel, ifosfamide 5 g/m 2 , and cisplatin 100 mg/m 2 were given 21 days apart with granulocyte colony-stimulating factor support, followed by resection of radiographic residua. The dose of paclitaxel was increased among cohorts with dose levels of 175, 215, and 250 mg/m 2 ; the largest dose was selected for the phase II part of the trial. RESULTS: Twenty-three (77%) of 30 patients achieved a complete response to chemotherapy alone, and one patient achieved a durable partial response with normal tumor markers. Therefore, 24 (80%) achieved a favorable response. Eleven patients with normalized markers after chemotherapy underwent resection of residual tissue, with only necrosis found in 10 and mature teratoma in one. Two patients relapsed, and 22 (73%) of the favorable responses remain durable at a median follow-up duration of 33 months. Myelosuppression was the major toxicity, and two patients had grade 3 neurotoxicity. CONCLUSION: Four cycles of TIP was associated with a high proportion of patients who achieved a complete response, a lack of relapse, and relative tolerability as an ifosfamide-containing salvage regimen for testicular GCTs. The high durable complete response proportion emphasizes the importance of patient selection according to prognostic factors for a favorable outcome to conventional-dose salvage therapy.
Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy
Authors: Ping Chen, Kaisa Huhtinen, Katja Kaipio, Piia Mikkonen, Viljami Aittomäki, Rony Lindell, Johanna Hynninen, Annika Auranen, Seija Grénman, Rainer Lehtonen, Olli Carpén, Sampsa Hautaniemi
Journal: Cancer Research (2015)

Disseminated high-grade serous ovarian cancer (HGS-OvCa) is an aggressive disease treated with platinum and taxane combination therapy. While initial response can be favorable, the disease typically relapses and becomes resistant to treatment. As genomic alterations in HGS-OvCa are heterogeneous, identification of clinically meaningful molecular markers for outcome prediction is challenging. We developed a novel computational approach (PSFinder) that fuses transcriptomics and clinical data to identify HGS-OvCa prognostic subgroups for targeted treatment. Application of PSFinder to transcriptomics data from 180 HGS-OvCa patients treated with platinum-taxane therapy revealed 61 transcript isoforms that characterize two poor and one good survival-associated groups (P = 0.007). These groups were validated in eight independent data sets, including a prospectively collected ovarian cancer cohort. Two poor prognostic groups have distinct expression profiles and are characteristic by increased hypermethylation and stroma-related genes. Integration of the PSFinder signature and BRCA1/2 mutation status allowed even better stratification of HGS-OvCa patients' prognosis. The herein introduced novel and generally applicable computational approach can identify outcome-related subgroups and facilitate the development of precision medicine to overcome drug resistance. A limited set of biomarkers divides HGS-OvCa into three prognostic groups and predicts patients in need of targeted therapies.
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1
Authors: M. Maurer, K. Weller, C. Bindslev-Jensen, A. Giménez-Arnau, P. J. Bousquet, J. Bousquet, G. W. Canonica, M. K. Church, K. V. Godse, C. E. H. Grattan, M. W. Greaves, M. Hide, D. Kalogeromitros, A. P. Kaplan, S. S. Saini, X. J. Zhu, T. Zuberbier
Journal: Allergy (2010)

To cite this article: Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317–330. Chronic spontaneous urticaria, formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is more common than previously thought. At any time, 0.5–1% of the population suffers from the disease (point prevalence). Although all age groups can be affected, the peak incidence is seen between 20 and 40 years of age. The duration of the disease is generally 1–5 years but is likely to be longer in more severe cases, cases with concurrent angioedema, in combination with physical urticaria or with a positive autologous serum skin test (autoreactivity). Chronic spontaneous urticaria has major detrimental effects on quality of life, with sleep deprivation and psychiatric comorbidity being frequent. It also has a large impact on society in terms of direct and indirect health care costs as well as reduced performance at work and in private life. In the majority of patients, an underlying cause cannot be identified making a causal and/or curative treatment difficult. Nonsedating H1-antihistamines are the mainstay of symptomatic therapy, but treatment with licensed doses relieves symptoms effectively in <50% of patients. Although guideline-recommended updosing up to fourfold increases symptom control in many patients, a substantial number of patients have only little benefit from H1-antihistamines. Consequently, there is a great need for new therapeutic strategies.
Molecular evolution in the gnd locus of Salmonella enterica.
Authors: G Thampapillai, R Lan, P R Reeves
Journal: Molecular Biology and Evolution (1994)

The gnd gene, the structural gene for 6-phosphogluconate dehydrogenase, was sequenced and analyzed in 34 isolates from different serovars of the seven subspecies of Salmonella enterica to provide comparative information on the evolution in this gene, which has been studied extensively in Escherichia coli. The gene tree obtained by the neighbor-joining method in general gave separate branches for each subspecies, with the few exceptions readily explained by recombination. There is evidence of recombination involving transfer of long (more than 400 bp) and short (30-150 bp) segments of DNA. Four of the six long-segment transfers detected are at the 5' end of the gene, and in all four cases a variant of the chi sequence is located close to the recombination junction and appears to have mediated the recombination events. We suggest that in these four cases and in a fifth case with intersubspecies transfer of the whole gnd gene, the adjacent rfb (O antigen) locus may have been transferred in the same event. The estimates of the number of synonymous substitutions per synonymous site, KS, and the number of nonsynonymous substitutions per nonsynonymous site, KA, within the E. coli and S. enterica gnd genes, and also between the two species show an interesting distribution, with KS being lower toward the ends of the gene and KA in particular being lower in the first than in the second domain. In S. enterica, synonymous sites also seem to be subjected to negative selection. The ratio of KA to KS was higher within S. enterica and E. coli than between them, which may indicate that intraspecies variation is essentially between clones and that mildly deleterious mutations can be fixed within clones, which would thus raise KA within species.